BCR-ABL,
Showing 26 - 50 of 1,180
3rd Line Therapy or More to Treat Adult CML- CP in Real World
Not yet recruiting
- Chronic Myeloid Leukemia
- Asciminib
- (no location specified)
Oct 16, 2023
Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Plasma Cell Myeloma Trial in Detroit (The DISCO
Recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- The DISCO App
- Usual Care
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
May 31, 2022
Real-World Usage of Asciminib Among Chronic Myeloid Leukemia in
Completed
- Chronic Myeloid Leukemia
-
East Hanover, New JerseyNovartis
Nov 20, 2023
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +13 more
- CMVpp65-A*0201 peptide vaccine
- +2 more
-
Duarte, California
- +4 more
Jan 4, 2023
Chronic Myelogenous Leukemia - Chronic Phase Trial in Avignon (APN and medical management, Medical management, Quality of life
Not yet recruiting
- Chronic Myelogenous Leukemia - Chronic Phase
- APN and medical management
- +3 more
-
Avignon, Provence-Alpes-Côte d'Azur, FranceCentre Hospitalier d'Avignon, Hôpital Henri Duffaut
Oct 13, 2023
Ex Vivo Drug Sensitivity Testing and Mutation Profiling
Completed
- Recurrent Childhood Acute Myeloid Leukemia
- +13 more
-
Miami, FloridaNicklaus Children's Hospital
Jan 18, 2023
Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and
Completed
- Leukemia
- No Intervention
-
Cambridge, MassachusettsTakeda
Feb 28, 2023
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in
Suspended
- Juvenile Myelomonocytic Leukemia
- +27 more
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid
Active, not recruiting
- Acute Myeloid Leukemia
- +9 more
- Carboplatin
- +3 more
-
Los Angeles, California
- +5 more
Jan 27, 2023
Chronic Myeloid Leukemia Any Phase Treated With Ponatinib at Any
Active, not recruiting
- Chronic Myeloid Leukemia, Chronic Phase
-
Jena, GermanyUniversity Hospital Jena
Jan 17, 2023
Leukemia, Myelogenous, Chronic Trial in Changchun (CTTQ Dasatinib tablet, Sprycel Dasatinib tablet)
Completed
- Leukemia, Myelogenous, Chronic
- CTTQ Dasatinib tablet
- Sprycel Dasatinib tablet
-
Changchun, Jilin, ChinaAffiliated Hospital of Changchun University of Traditional Chine
Dec 7, 2022
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Recruiting
- Recurrent Childhood Acute Myeloid Leukemia
- +17 more
-
Miami, FloridaNicklaus Children's Hospital
May 13, 2023
Chronic Myelogenous Leukemia Trial in Houston (TGRX-678)
Not yet recruiting
- Chronic Myelogenous Leukemia
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Oct 12, 2023
"Peripheral Blood Dipeptidylpeptidase IV Positive Leukemic Stem
Not yet recruiting
- Chronic Myeloid Leukemia, Chronic Phase
-
Sohag, EgyptSohag University Hospital
Sep 14, 2022
Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)
Not yet recruiting
- Tyrosine Kinase Inhibitors
- Chronic Myeloid Leukemia
- treatment of TKI in CML
-
Poitiers, FranceChu Poitiers
Feb 21, 2023
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Rochester (Hyperbaric oxygen)
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Hyperbaric oxygen
-
Rochester, New YorkWilmot Cancer Institute, University of Rochester
May 16, 2022
CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)
Recruiting
- CML
- Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
-
Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, ArgentinaFUNDALEU
Jun 29, 2023
CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))
Recruiting
- CML, Chronic Phase
- CML, Accelerated Phase
- HS-10382(Part 1: Dose escalation)
- HS-10382(Part 2: Dose expansion)
-
Wuhan, Hubei, ChinaUnion Hospital affiliated to Tongji Medical College of Huazhong
Jan 12, 2023
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia Trial in Philadelphia (Text
Recruiting
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Phase Chronic Myelogenous Leukemia
- Text Message-Based Navigation Intervention
- Survey Administration
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Apr 7, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia
Completed
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +14 more
- Aldesleukin
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Jul 31, 2022
Ponatinib in CML Patients in Chronic Phase
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- Therapeutic drug monitoring
- Molecular Response
-
Cagliari, Italy
- +4 more
Nov 3, 2023
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +36 more
- Cyclophosphamide
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 23, 2023
Treatment Free Remission (TFR) in CML Patients (CML-CP)Study
Not yet recruiting
- Chronic Myeloid Leukemia
- Treatment-free Remission
- TFR(Treatment-Free Remission)
- (no location specified)
Jun 27, 2022